Amneal to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Amneal (Nasdaq: AMRX) announced executives will participate in two investor conferences and that presentations will be webcast. Chirag Patel, Co‑Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will join the Piper Sandler 2025 Healthcare Conference for a fireside chat on December 3, 2025 at 9:30 AM EST in New York. They will also present at the J.P. Morgan 2026 Healthcare Conference on January 13, 2026 at 4:30 PM PST in San Francisco. A webcast and limited-time replays will be available on Amneal's Investor Relations site.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AMRX declined 2.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves with PBH, INDV, HCM, and PRGO down and BHC up 2.94%, indicating stock-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | FDA approval | Positive | +2.0% | U.S. FDA approval for epinephrine injection vials for hospital use. |
| Dec 05 | Clinical data update | Positive | +2.4% | Positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s. |
| Dec 02 | Investor conferences | Neutral | -2.5% | Announcement of participation in Piper Sandler and J.P. Morgan conferences. |
| Dec 02 | FDA approval | Positive | -2.5% | FDA approval of albuterol sulfate inhalation aerosol, generic PROAIR HFA. |
| Dec 01 | FDA approval | Positive | -2.5% | FDA approval of cyclosporine ophthalmic emulsion 0.05%, generic RESTASIS. |
Recent fundamentally positive events (FDA approvals, positive trial data) generally coincided with positive price reactions, while neutral or logistical news like conference participation saw negative moves, indicating the stock has sometimes sold off on non-fundamental headlines.
Over the last several days, Amneal reported multiple U.S. FDA approvals for epinephrine injection, albuterol sulfate inhalation aerosol, and cyclosporine ophthalmic emulsion, plus positive interim Phase 4 ELEVATE-PD results for CREXONT. These fundamentally positive updates saw mixed price reactions, with some approvals followed by -2.52% moves and others like the Dec 9 epinephrine approval up 2.01%. The current conference participation notice fits a pattern of routine investor-relations activity alongside a busy regulatory and clinical period.
Market Pulse Summary
This announcement highlights Amneal’s continued engagement with the investment community through the Piper Sandler 2025 and J.P. Morgan 2026 healthcare conferences, with webcasts and replays available to investors. In context, it follows several material updates, including multiple U.S. FDA approvals and positive Phase 4 data, which have driven mixed price reactions. Historically, conference headlines have led to modest average moves of about 0.94%, suggesting investors may focus more on upcoming fundamental data and regulatory milestones than on these scheduling details.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:
Piper Sandler 2025 Healthcare Conference
Date: December 3, 2025
Fireside Chat: Wednesday, December 3, 2025, at 9:30AM EST
Location: New York, NY
J.P. Morgan 2026 Healthcare Conference
Date: January 12-15, 2026
Presentation: Tuesday, January 13, 2026, at 4:30PM PST
Location: San Francisco, CA
A webcast of the presentations will be available on Amneal’s Investor Relations website at www.amneal.com/investors. Replays will be available for a limited time following each event.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
FAQ
When is Amneal's fireside chat at the Piper Sandler 2025 Healthcare Conference (AMRX)?
Who from Amneal (AMRX) will present at the Piper Sandler conference on December 3, 2025?
When and where will Amneal present at the J.P. Morgan 2026 Healthcare Conference (AMRX)?
How can investors watch Amneal's (AMRX) conference presentations online?
Will replays of Amneal's (AMRX) presentations be available after the events?
What executives will represent Amneal (AMRX) at investor conferences in December 2025 and January 2026?
